US EditionTrump announces reforms to accelerate access to psychedelic drug treatments
The order directs faster FDA reviews and a $50 million federal research push as officials seek new treatments for veterans with PTSD and depression.
- On Saturday, April 18, 2026, President Donald Trump signed an executive order directing federal agencies to expedite research on psychedelic drugs, including ibogaine, and committed $50 million to federal research.
- Health Secretary Robert F. Kennedy Jr. and podcaster Joe Rogan joined Trump at the Oval Office, highlighting veteran mental health crises; Kennedy noted thousands of veterans travel to Mexico for treatments due to domestic restrictions.
- Trump cited a 2024 Stanford University study showing 30 special operations veterans experienced an 80% to 90% reduction in depression and anxiety symptoms within one month, though critics warn ibogaine remains classified as Schedule I with known cardiotoxicity risks.
- FDA Commissioner Marty Makary announced the agency will issue national priority vouchers next week to accelerate reviews, targeting approvals within weeks, while opening a Right-to-Try pathway for terminally ill patients.
- While ibogaine remains Schedule I, the order signals a shift from underground use to federal acknowledgment, potentially encouraging states to fund university research programs and reshaping access for veterans long-term.
202 Articles
202 Articles
Definium Therapeutics Applauds White House Executive Order to Accelerate Mental Health Innovation and Expand Access to Psychedelic Medical Treatments
NEW YORK -- Definium Therapeutics, Inc. (“Definium” or the “Company”), a late-stage clinical biopharmaceutical company developing a new generation of therapies targeting the underlying causes of psychiatric and neurological disorders, today issued the following statement supporting the newly signed White House Executive Order aimed at accelerating research, development, and responsible access to innovative treatments for serious mental illness, …
Donald Trump signs order to fast-track research on psychedelic drugs
WASHINGTON — U.S. President Donald Trump on Saturday announced an easing of restrictions on research into psychedelic drugs — such as so-called "magic mushrooms" — that have shown promise in treating people with mental health conditions.
With Executive Order, Trump Accelerates Psychedelic Research, Joking: ‘Can I Have Some?’
‘In many cases, these experimental treatments have shown life-changing potential for those suffering from severe mental illness and depression, including our cherished veterans,’ the president says.
Coverage Details
Bias Distribution
- 59% of the sources are Center
Factuality
To view factuality data please Upgrade to Premium
